Bioreactor technologies to support liver function in vitro

被引：101

作者：

Ebrahimkhani, Mohammad R. ^{[1
]}

Neiman, Jaclyn A. Shepard ^{[1
,2
]}

Raredon, Micha Sam B. ^{[1
,3
]}

Hughes, David J. ^{[4
]}

Griffith, Linda G. ^{[1
,5
]}

机构：

[1] MIT, Dept Biol Engn, Cambridge, MA 02139 USA

[2] MIT, Dept Chem Engn, Cambridge, MA 02139 USA

[3] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA

[4] CN Bio Innovat Ltd, Oxford, England

[5] MIT, Ctr Gynepathol Res, Cambridge, MA 02139 USA

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2014年 / 69卷

基金：

美国国家科学基金会;

关键词：

Tissue engineering; Bioreactor; Microfluidic; Organ on chip; Hepatocytes; Liver non-parenchymal cells; Drug development; Drug toxicity; SINUSOIDAL ENDOTHELIAL-CELLS; DRUG-METABOLIZING-ENZYMES; HEPATIC STELLATE CELLS; BIOARTIFICIAL LIVER; RAT HEPATOCYTES; PERFUSION-CULTURE; MICROFLUIDIC CELL; ARTIFICIAL LIVER; SHEAR-STRESS; CARCINOEMBRYONIC ANTIGEN;

D O I：

10.1016/j.addr.2014.02.011

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Liver is a central nexus integrating metabolic and immunologic homeostasis in the human body, and the direct or indirect target of most molecular therapeutics. A wide spectrum of therapeutic and technological needs drives efforts to capture liver physiology and pathophysiology in vitro, ranging from prediction of metabolism and toxicity of small molecule drugs, to understanding off-target effects of proteins, nucleic acid therapies, and targeted therapeutics, to serving as disease models for drug development. Here we provide perspective on the evolving landscape of bioreactor-based models to meet old and new challenges in drug discovery and development, emphasizing design challenges in maintaining long-term liver-specific function and how emerging technologies in biomaterials and microdevices are providing new experimental models. (C) 2014 Elsevier B.V. All rights reserved.

引用

页码：132 / 157

页数：26

共 227 条

[1]

Regulation of drug-metabolizing enzymes and transporters in inflammation [J].